Sie befinden sich hier
Inhalt
24th January 2023
Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells.
Read the press releases for details:
Press release of the German Cancer Research Center in Heidelberg (English Language):
24.01.2023 What keeps the immune defense in brain tumors functional
Press release of the Medical Faculty Mannheim (German language):
24.01.2023 Was die Abwehrzellen in Hirntumoren funktionsfähig hält
Joint press release of the German Cancer Research Center (DKFZ), Mannheim University Medical Center (UMM), Heidelberg University Hospital (UKHD) and the German Consortium for Translational Cancer Research (DKTK)
Original scientific publication:
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Michael Kilian, Ron Sheinin, Chin Leng Tan, Mirco Friedrich, Christopher Krämer, Ayelet Kaminitz, Khwab Sanghvi, Katharina Lindner, Yu-Chan Chih, Frederik Cichon, Benjamin Richter, Stefanie Jung, Kristine Jähne, Miriam Ratliff, Robert M. Prins, Nima Etminan, Andreas von Deimling, Wolfgang Wick, Asaf Madi, Lukas Bunse, Michael Platten:
2023, Cancer Cell 41:1-17